Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tci GeneROCO:6879 60 Return-on-Tangible-Asset is 7.10% as of Dec. 2025, which is 16% below its 10-year median of 8.43. GuruFocus rates ROCO:6879 with a GF Score™ of 60/100 and a GF Value™ of NT$48.30 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,414 Biotechnology companies, Tci Gene ranks better than 85.36% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Tci Gene's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$74.9 Mil. Tci Gene's average total tangible assets for the quarter that ended in Dec. 2025 was NT$1,055.3 Mil. Therefore, Tci Gene's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 7.10%.
The historical rank and industry rank for Tci Gene's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:6879'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.01 Med: 8.43 Max: 24.65
Current: 3.8
During the past 7 years, Tci Gene's highest Return-on-Tangible-Asset was 24.65%. The lowest was 1.01%. And the median was 8.43%.
ROCO:6879's Return-on-Tangible-Asset is ranked better than 85.36% of 1414
companies
in the Biotechnology industry
Industry Median: -36.16
vs ROCO:6879: 3.80
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Tci Gene Return-on-Tangible-Asset Related Terms
Tci Gene Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Tci Gene's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Tci Gene's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Tci Gene's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 7.10% mean?
Tci Gene (ROCO:6879) has a Return-on-Tangible-Asset of 7.10% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tci Gene and its competitors. This is 16% below median its historical median of 8.43. Over the past decade, Tci Gene's Return-on-Tangible-Asset has ranged from 1.01 to 24.65. According to the industry distribution chart, Tci Gene ranks #207 out of 1414 companies in the Biotechnology industry, placing it in the top 14.6%.
Is Tci Gene's Return-on-Tangible-Asset too high?
Tci Gene's current Return-on-Tangible-Asset of 7.10% is 16% below median its 10-year median of 8.43. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 24.65. Based on the distribution chart, Tci Gene ranks #207 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tci Gene has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #207 out of 1414 companies for Return-on-Tangible-Asset. This places Tci Gene in the top 15% of its industry — outperforming the majority of peers. Historically, Tci Gene's own Return-on-Tangible-Asset has ranged from 1.01 to 24.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Tci Gene and its competitors. Tci Gene's current Return-on-Tangible-Asset is 7.10%, which is 16% below median its own 10-year median of 8.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.30, compared to a current price of NT$34.00 — trading 29.6% below its estimated fair value. The current Return-on-Tangible-Asset is 7.10%, which is 16% below median its 10-year median of 8.43. Tci Gene's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current Return-on-Tangible-Asset is 7.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$34.00 is trading 29.6% below its estimated GF Value™ of NT$48.30.
GuruFocus considers Tci Gene to be Possible Value Trap.
Key valuation signals for ROCO:6879:
Return-on-Tangible-Asset: 7.10% (16% below median its 10-year median of 8.43)
GF Value™: NT$48.30 vs. price of NT$34.00 (29.6% below fair value)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
60GF Score
Get the complete analysis for ROCO:6879
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
